Kardigan’s Prolaio platform uses wearable sensors and FDA-cleared algorithms to track cardiovascular signals between clinic visits, supporting its precision cardiology trials.
Clinical-stage Kardigan recently closed its IPO, spotlighting a precision cardiology pipeline focused on more targeted treatments for heart disease.
Kardigan (KARD) raised $460 million in gross proceeds on its Nasdaq debut, selling 28.75 million shares at $16 each. The company is advancing therapies for genetic dilated cardiomyopathy, calcific aortic valve stenosis and blood pressure management after hospitalization for acute severe hypertension.
Kardigan is developing therapies for defined patient groups whose diseases may be driven by specific genetic or biological factors. Its three main clinical programs are aimed at areas where care remains limited: genetic dilated cardiomyopathy (DCM), moderate calcific aortic valve stenosis and blood pressure management after hospitalization for acute severe hypertension.
The company’s lead program, danicamtiv, is being studied for genetic DCM, a condition where the heart’s chambers stretch and weaken, reducing the heart’s ability to pump blood. Kardigan is focusing on forms of DCM linked to changes in genes such as MYH7 and TTN, which can affect how the heart muscle contracts.
Danicamtiv is an investigational oral therapy designed to boost the function of myosin, a motor protein that helps heart muscle contract. The drug is designed to address impaired muscle contraction in forms of DCM linked to specific gene changes.
MyoKardia originally discovered danicamtiv, and Kardigan later licensed the therapy from Bristol Myers Squibb. Kardigan is now evaluating danicamtiv in KINSHIP-DCM, a Phase IIb/III trial, with main results from the Phase IIb portion expected in the first half of 2027.
Get industry leading pharma and biotech news, events and expert insights delivered to your inbox.
Kardigan’s second program, ataciguat, is targeting a treatment gap in aortic valve disease. The drug is being developed for moderate calcific aortic valve stenosis, a disease where the heart’s main valve hardens due to calcium buildup.
Moderate-stage patients are often monitored until their disease progresses to a stage requiring valve replacement. Ataciguat targets valve calcification, the process that stiffens valve tissue, to slow disease progression before replacement surgery may be needed.
Kardigan is evaluating ataciguat in KATALYST-AV, a Phase IIb trial. The company expects 24-week data in the first half of 2027 and 48-week data in the second half of 2027.
The third late-stage program, tonlamarsen, is being studied for blood pressure management after hospitalization for acute severe hypertension.
Tonlamarsen is a once-monthly injectable antisense oligonucleotide designed to reduce angiotensinogen, a liver-produced protein involved in blood pressure regulation. Kardigan is investigating whether tonlamarsen can provide more sustained blood pressure control after hospital discharge, when patients may remain at risk of repeat blood pressure crises and rehospitalization.
Kardigan initiated the KARDINAL-ASH Phase II trial in the second quarter of 2026 and expects main results in the first half of 2027.
Prolaio, Kardigan’s data and analytics platform, uses wearable sensors and FDA-cleared algorithms to collect cardiovascular data from patients in daily life. By tracking measures such as heart rhythm, blood pressure and activity levels, Prolaio gives researchers a more detailed view of patient health between doctor visits.
The company is using Prolaio across its clinical trials, including home-based data collection in studies of danicamtiv, ataciguat and tonlamarsen. Kardigan expects study updates from all three late-stage programs in 2027.
Recent cardiovascular R&D is also moving toward more targeted approaches. These include RNA-based medicines, AI-guided discovery and therapies aimed at genetic drivers of heart disease. In approvals, Cytokinetics’ Myqorzo (aficamten), approved in late 2025, acts on cardiac myosin, a protein involved in heart muscle contraction.
In hypertension, AstraZeneca’s Baxfendy (baxdrostat) was approved in May 2026. Roche and Alnylam’s zilebesiran has also advanced to global Phase III testing, targeting angiotensinogen, the same blood pressure-related protein involved in Kardigan’s tonlamarsen program.
Atrium Therapeutics also launched earlier this year with about $270 million to develop RNA-based medicines for rare inherited heart muscle diseases. Its early programs focus on conditions linked to PRKAG2 and PLN gene changes, which can affect how the heart muscle works.
If you want your company to be featured on Xtalks.com, please email [email protected].
Join or login to leave a comment
JOIN LOGIN